Absci Corporation
2.86
0.15 (5.54%)
At close: Jan 15, 2025, 3:59 PM
2.85
-0.35%
After-hours Jan 15, 2025, 04:57 PM EST

Company Description

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States.

Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process.

Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Absci Corporation
Absci Corporation logo
Country United States
IPO Date Jul 22, 2021
Industry Biotechnology
Sector Healthcare
Employees 155
CEO Sean McClain

Contact Details

Address:
18105 SE Mill Plain Boulevard
Vancouver, Washington
United States
Website https://www.absci.com

Stock Details

Ticker Symbol ABSI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001672688
CUSIP Number 00091E109
ISIN Number US00091E1091
Employer ID 45-3931977
SIC Code 8731

Key Executives

Name Position
Sean McClain Founder, Chief Executive Officer, President & Director
Dr. Zachariah Jonasson Ph.D. Chief Business Officer & Chief Financial Officer
Karin Wierinck Chief People Officer
Shelby Walker J.D. Chief Legal Officer
Alexander Khan CPA Vice President of Finance & Head of Investor Relations
Dr. Andreas Busch Ph.D. Chief Innovation Officer & Member of Scientific Advisory Board
Jens Plassmeier Ph.D. Senior Vice President of Synthetic Biology R&D
Melissa Patterson Ph.D. Chief of Staff
Todd Bedrick CPA Senior Vice President & Chief Accounting Officer
Wen Sha Chief of Staff

Latest SEC Filings

Date Type Title
Jan 10, 2025 SCHEDULE 13G Filing
Dec 09, 2024 4 Filing
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership b...
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 12, 2024 8-K Current Report
Nov 08, 2024 SC 13G Statement of acquisition of beneficial ownership b...
Oct 18, 2024 SC 13G Statement of acquisition of beneficial ownership b...
Oct 16, 2024 4 Filing
Oct 16, 2024 4 Filing
Oct 16, 2024 4 Filing